Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576
伊布替尼联合奥妥珠单抗作为慢性淋巴细胞白血病一线治疗方案，可降低输注相关反应发生率，并在停用伊布替尼后维持缓解：一项单臂、开放标签的 1b/2 期临床试验 NCT0231576
期刊:Advances in Hematology
影响因子:
doi:10.1155/2022/4450824
Castro, Januario E; Lengerke-Diaz, Paula A; Velez Lujan, Juliana; Choi, Michael Y; Moreno-Cortes, Eider F; Forero, Jose V; Garcia-Robledo, Juan Esteban; Jacobs, Chaja; McCarthy, Colin; Heinen, Alaina; Amaya-Chanaga, Carlos I; Kipps, Thomas J
